A Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates With Muscle-Invasive Bladder Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 18 Jul 2018
At a glance
- Drugs Paclitaxel (Primary) ; Trastuzumab (Primary)
- Indications Bladder cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 04 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 03 Aug 2012 Planned end date changed from 1 Jul 2012 to 1 May 2014 as reported by ClinicalTrials.gov.